• • MANAGEMENT TEAM
  • BOARD OF DIRECTORS
  • SCIENTIFIC / CLINICAL ADVISORY BOARD
  • INVESTORS
• • PARP INHIBITOR PROGRAM
  • BSI-201: CLINICAL PARP INHIBITOR (IV)
  • BSI-401: PRECLINICAL PARP INHIBITOR (ORAL)
  • BSI-301: PRECLINICAL IODOTHYRONINE PROGRAM

Home

Product Pipeline

Learn more about our PARP Inhibitor Program

• BSI-201
• Other PARP inhibitor candidates
• Iodothyronine Program

BiPar Sciences is a biopharmaceutical company developing and commercializing potential new classes of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.